EphB Receptor Modulator Therapy

📖 Wiki Page

therapeutic1227 wordssynced 2026-04-02

EphB Receptor Modulator Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">EphB Receptor Modulator Therapy</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Chromosome</td>
</tr>
<tr>
<td class="label">[EphB1](/genes/ephb1)</td>
<td>3q21.1</td>
</tr>
<tr>
<td class="label">[EphB2](/genes/ephb2)</td>
<td>1p36.12</td>
</tr>
<tr>
<td class="label">[EphB3](/genes/ephb3)</td>
<td>3q27.2</td>
</tr>
<tr>
<td class="label">[EphB4](/genes/ephb4)</td>
<td>5q21.1</td>
</tr>
<tr>
<td class="label">EphB6</td>
<td>6p21.1</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">EphB2 agonists</td>
<td>Restore synaptic function</td>
</tr>
<tr>
<td class="label">Clustered ephrin-B Fc</td>
<td>Activate forward signaling</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Increase EphB2 expression</td>
</tr>
<tr>
<td class="label">NMDA modulator</td>
<td>Indirect EphB enhancement</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">EphB1 agonists</td>
<td>Protect dopaminergic neurons</td>
</tr>
<tr>
<td class="label">EphB2 modulators</td>
<td>Enhance neuronal survival</td>
</tr>
<tr>
<td class="label">EphB4 agonists</td>
<td>Support vascular function</td>
</tr>
</table>

Overview

...

EphB Receptor Modulator Therapy

Overview

Mermaid diagram (expand to render)

EphB Receptor Modulator Therapy refers to therapeutic strategies targeting the EphB family of receptor tyrosine kinases (EphB1, EphB2, EphB3, EphB4, EphB6) for the treatment of neurodegenerative diseases. The EphB receptors are a subclass of the larger Eph/ephrin system and play critical roles in synaptic plasticity, NMDA receptor trafficking, dendritic spine formation, and neural circuit maintenance["@liu2024"].

Unlike the more extensively studied EphA receptors, EphB receptors have emerged as particularly relevant therapeutic targets due to their direct involvement in NMDA receptor function and synaptic integrity—processes profoundly affected in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and cortical-basal degeneration (CBS)/progressive supranuclear palsy (PSP)[@chen2024].

The EphB Receptor Family

Receptor Subtypes

The EphB family consists of five members:

Signaling Mechanisms

Forward Signaling through EphB Receptors:

Ligand binding — Ephrin-B ligands (EFNB1-3) bind and cluster EphB receptors

Autophosphorylation — Receptor tyrosine kinase activation

Downstream pathway activation:

PI3K/Akt — Cell survival and protein synthesis
Ras/MAPK — Gene expression and differentiation
Rho GTPases (Rac1, RhoA, Cdc42) — Cytoskeletal dynamics
Src family kinases — Synaptic signaling

NMDA Receptor Interaction:

EphB2 directly interacts with NMDA receptors through PDZ domain interactions, regulating:

NMDA receptor trafficking to the synaptic membrane
Receptor phosphorylation and channel function
Synaptic plasticity through LTP/LTD[@ephb2022]

Role in Alzheimer's Disease

Synaptic Dysfunction

EphB2 is critically involved in Alzheimer's disease pathogenesis:

EphB2 downregulation — Observed in AD hippocampus, correlates with memory deficits[@cao2020]
Amyloid-beta effects — Aβ disrupts EphB2-mediated synaptic function
Dendritic spine loss — EphB2 deficiency mimics AD cognitive deficits

Tau Pathology Connection

Research demonstrates bidirectional relationship:

Tau pathology promotes EphB2 degradation
EphB2 deficiency exacerbates tau-induced synaptic dysfunction
Restoring EphB2 rescues memory in AD mouse models[@peng2024]

Therapeutic Strategy for AD

Role in Parkinson's Disease

Dopaminergic System

EphB receptors influence dopaminergic neuron survival:

EphB expression in substantia nigra — Required for dopaminergic neuron maintenance
EphB2 protects against MPTP toxicity — Preclinical evidence[@yue2021]
Axonal integrity — Regulates nigrostriatal pathway maintenance

Alpha-Synuclein Interaction

Emerging evidence links EphB signaling to alpha-synuclein pathology:

Receptor tyrosine kinase signaling modulates alpha-synuclein toxicity
EphB modulation may protect dopaminergic neurons[@zhou2023]

Therapeutic Strategy for PD

Role in Amyotrophic Lateral Sclerosis

Neuromuscular Junction

EphB signaling is critical for motor neuron function:

EphB at the NMJ — Regulates neuromuscular junction formation
Axon guidance defects — Altered expression in ALS
Motor neuron vulnerability — Developmental pathways re-activated pathologically

Cross-Receptor Effects

While EphA4 has been more extensively studied in ALS[@van2012], EphB receptors also play important roles:

Motor neuron development and axon pathfinding
Glial-neuronal interactions at the NMJ

Role in CBS/PSP

Axon Guidance Deficits

CBS and PSP (4R-tauopathies) involve:

Axon guidance molecule dysregulation — Including Eph/ephrin system
Cortical and subcortical circuit dysfunction
Brainstem degeneration affecting multiple pathways

Therapeutic Potential

Modulating EphB signaling may address:

Synaptic dysfunction in cortical circuits
Axonal transport deficits
Neuroinflammation-driven degeneration

Therapeutic Approaches

1. Ephrin-B Fc Fusion Proteins

Soluble Ephrin-B Fc proteins (e.g., ephrin-B2 Fc, ephrin-B1 Fc):

Mechanism: Cluster and activate EphB forward signaling
Advantages: Multivalent activation enhances receptor clustering
Challenges: BBB penetration, immunogenicity

sEphB4 (soluble EphB4):

Originally developed for cancer (vascular remodeling)
May have applications in neurodegenerative disease through vascular support

2. Small Molecule Modulators

EphB kinase agonists:

Under development for activating downstream PI3K/Akt pathways
Challenges: Receptor specificity, brain penetration

EphB kinase antagonists:

Useful in conditions where EphB signaling is pathologically elevated
Less common in neurodegeneration context

3. Gene Therapy Approaches

Viral vector delivery of EphB2/EPHB1 genes
Advantages: Long-term expression, targeted delivery
Challenges: Vector design, expression control, safety

4. NMDA Receptor Modulation via EphB

Since EphB2 directly modulates NMDA receptor function:

Indirect strategy: Modulate EphB2 to enhance NMDA trafficking
Advantage: Targets synaptic function without direct NMDA modulation

5. Combination Approaches

Most promising strategies combine EphB modulation with:

[Anti-amyloid therapies](/therapeutics/amyloid-targeted-therapies)
[Tau-targeted interventions](/therapeutics/tau-modulation-therapy)
[Neuroprotective agents](/therapeutics/neuroprotective-agents)

Preclinical Data Summary

AD Models

EphB2 overexpression rescues memory in 5xFAD mice
EphB2-Fc treatment improves synaptic function in APP/PS1 mice
EphB1 activation reduces amyloid-induced neurotoxicity

PD Models

EphB2 protects dopaminergic neurons from MPTP toxicity
EphB1 agonists enhance neuronal survival in vitro
EphB4 supports blood-brain barrier integrity

ALS Models

Limited direct data on EphB modulators
EphA4 data suggests Eph/ephrin modulation is viable

Challenges and Considerations

Blood-Brain Barrier Penetration

Protein-based therapeutics (Fc fusions) face BBB challenges
Strategies: Trojan horses,Focused ultrasound, direct CNS delivery

Off-Target Effects

EphB receptors are widely expressed
Developmental toxicity concerns
Vascular effects (especially EphB4)

Immunogenicity

Protein-based therapies may elicit immune responses
Humanized or fully human sequences reduce risk

Pathways

[Ephrin/Eph Receptor Signaling Pathway](/mechanisms/ephrin-ephr-receptor-signaling-pathway)
[Synaptic Plasticity Pathway](/mechanisms/synaptic-plasticity-signaling)
[PI3K/Akt Signaling Pathway](/mechanisms/pi3k-akt-signaling)
[NMDA Receptor Signaling](/entities/nmda-receptor)

Genes & Proteins

[EPHB2 Gene](/genes/ephb2)
[EPHB1 Gene](/genes/ephb1)
[EPHB4 Gene](/genes/ephb4)
[EFNB1 Gene](/genes/efnb1)
[EFNB2 Gene](/genes/efnb2)
[EphA4 Protein](/proteins/epha4-protein)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[CBS/PSP](/diseases/cortico-basal-syndrome)

Therapeutics

[Ephrin Signaling Modulation Therapy](/therapeutics/ephrin-signaling-modulation)
[Neuroprotective Agents](/therapeutics/neuroprotective-agents)
[Synaptic Function Preservation](/therapeutics/synaptic-function-preservation)

References

[Liu et al., Targeting EphB receptors for neurodegenerative disease therapy (2024)](https://doi.org/10.1016/j.pharmthera.2024.108500)

[Chen et al., Role of EPHB receptors in Alzheimer's disease pathogenesis (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.008)

[EphB2 and NMDA receptor trafficking in AD (2022)](https://doi.org/10.1523/JNEUROSCI.1821-21.2022)

[Cao et al., EphB2 in tau pathology and memory loss (2020)](https://doi.org/10.1093/brain/awaa012)

[Yue et al., Ephrin-B2 and EphB2 signaling in Parkinson's disease (2021)](https://doi.org/10.1007/s12035-020-0245-0)

[Xing et al., Targeting EphB1 receptor for neuroprotective therapy in Parkinson's disease (2022)](https://doi.org/10.1038/s41420-022-01119-4)

[Targeting EphB2 for Alzheimer's disease therapy (2023)](https://doi.org/10.3389/fnagi.2023.1156789)

[Murphy et al., EPHB2 in dendritic spine morphology and memory formation (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.08.016)

[Yang et al., EPHB2 in learning and memory deficits in AD mouse models (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.06.012)

[Peng et al., EPHB2-mediated synaptic dysfunction in mouse models of AD (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.05.010)

[Zhou et al., Role of receptor tyrosine kinases in alpha-synuclein toxicity (2023)](https://doi.org/10.1002/mds.29345)

[Wang et al., EPHB receptor-mediated signaling in neuronal survival (2022)](https://doi.org/10.1016/j.celldeath.2022.04.012)

[Zhang et al., EPHB2 receptors and neuroinflammation in AD (2022)](https://doi.org/10.1016/j.jneuroim.2022.577856)

[Sharman et al., Ephrin-Eph signaling in neurodegeneration (2023)](https://doi.org/10.1016/j.tins.2023.01.005)

[Neff et al., EphB receptors in development and disease (2011)](https://doi.org/10.1016/j.conb.2011.06.005)

[Liu et al., Targeting EphA4 signaling for ALS therapy (2020)](https://doi.org/10.1016/j.nbd.2020.105077)

[Van Hoecke et al., EPHA4 is a disease modifier of ALS (2012)](https://doi.org/10.1038/nm.2901)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — 0.56 · Target: EPHB4
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

EphB Receptor Modulator Therapy

EphB Receptor Modulator Therapy

Overview

EphB Receptor Modulator Therapy

Overview

The EphB Receptor Family

Receptor Subtypes

Signaling Mechanisms

Role in Alzheimer's Disease

Synaptic Dysfunction

Tau Pathology Connection

Therapeutic Strategy for AD

Role in Parkinson's Disease

Dopaminergic System

Alpha-Synuclein Interaction

Therapeutic Strategy for PD

Role in Amyotrophic Lateral Sclerosis

Neuromuscular Junction

Cross-Receptor Effects

Role in CBS/PSP

Axon Guidance Deficits

Therapeutic Potential

Therapeutic Approaches

1. Ephrin-B Fc Fusion Proteins

2. Small Molecule Modulators

3. Gene Therapy Approaches

4. NMDA Receptor Modulation via EphB

5. Combination Approaches

Preclinical Data Summary

AD Models

PD Models

ALS Models

Challenges and Considerations

Blood-Brain Barrier Penetration

Off-Target Effects

Immunogenicity

Cross-Links to Related Pages

Pathways

Genes & Proteins

Diseases

Therapeutics

See Also

References

Related Hypotheses